Your browser doesn't support javascript.
loading
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
Landi, Doriana; De Rossi, Nicola; Zagaglia, Sara; Scarpazza, Cristina; Prosperini, Luca; Albanese, Maria; Buttari, Fabio; Mori, Francesco; Marfia, Girolama Alessandra; Sormani, Maria Pia; Capra, Ruggero; Centonze, Diego.
Affiliation
  • Landi D; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • De Rossi N; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Zagaglia S; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Scarpazza C; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Prosperini L; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Albanese M; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Buttari F; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Mori F; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Marfia GA; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Sormani MP; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Capra R; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
  • Centonze D; From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.
Neurology ; 88(12): 1144-1152, 2017 03 21.
Article in En | MEDLINE | ID: mdl-28228569
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukoencephalopathy, Progressive Multifocal / Plasmapheresis / Treatment Outcome / Natalizumab / Immunologic Factors Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Neurology Year: 2017 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukoencephalopathy, Progressive Multifocal / Plasmapheresis / Treatment Outcome / Natalizumab / Immunologic Factors Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Neurology Year: 2017 Document type: Article Country of publication: United States